期刊文献+

人脑胶质瘤组织MGMT和EGFR及Ki-67表达临床意义分析 被引量:16

Expression and clinical significance of MGMT,EGFR and Ki-67 in human gliomas
原文传递
导出
摘要 目的:探讨人脑胶质瘤组织中O6-甲基鸟嘌呤DNA甲基转移酶(MGMT)、表皮生长因子受体(EGFR)和细胞增殖相关核蛋白Ki-67的表达及其相关性。方法:选取64例脑胶质瘤组织标本,采用免疫组织化学染色法检测MGMT、EGFR及Ki-67的表达。结果:MGMT、EGFR、Ki-67总体阳性率分别为76.6%、59.4%和56.3%。在Ⅰ、Ⅱ、Ⅲ、Ⅳ级胶质瘤中,MGMT阳性表达率分别为0、58.8%、70.0%和100.0%;EGFR阳性表达率分别0、41.2%、60.0%和76.0%;Ki-67阳性表达率分别为0、23.5%、65.0%和76.0%。MGMT、EGFR和Ki-67的阳性表达率在脑胶质瘤不同病理分级间差异有统计学意义,P值分别为0.001、0.043和0.002;且三者的表达强度与胶质瘤病理分级呈正相关性,r值分别为0.315、0.273和0.400,P值分别为0.011、0.029和0.001。3种检测指标的阳性表达率与发病年龄及性别均无明显的相关性,差异无统计学意义,P>0.05。分层分析发现,Ki-67的表达与MGMT和EGFR的表达有相关性,r分别为0.296和0.466,P值分别为0.018和0.000。结论:人脑胶质瘤中MGMT、EGFR及Ki-67的表达与病理分级均有相关性,测定三者的表达水平可评价胶质瘤细胞的恶性程度,对胶质瘤预后判断可能有指导作用。 OBJECTIVE:To investigate the expression of O6-methylguanine-DNA-Methyltransferase (MGMT),epi- dermal growth factor reeeptor(EGFR) and Ki-67 in human glioma cell, as well as the relations among the three in glioma. METHODS:Total of 64 samples of glioma were used to detect the expression of MGMT,EGFR and Ki 67 by using immu- nohistochemistry. RESULTS: The positive expression rate of MGMT,EGFR and Ki-67 in the glioma tissue were 76.6%, 59.4% and 56.3 %. In different grades(WHO Grade Ⅰ , Ⅱ , Ⅲ , Ⅳ) of glioma sample,the positive expression rate of MG- MT were 0,58.8% ,70.0% and 100.0% ; the positive expression rate of EGFR were 0,41.2% ,60.0% and 76.0% ; the positive expression rate of Ki-67 were 0,23.5% ,65.0% and 76.0%. The expression of MGMT,EGFR and Ki-67 were significantly different in pairwise comparison of every two grades of results among all of them,and P values were 0. 001, 0. 043 and 0. 002. They were correlated well with Pathological grades (MGMT r=0. 315,P--0. 011; EGFR r=0. 273, P= 0. 029; Ki-67 r= 0. 400, P= 0. 001). There was no significant difference in the MGMT, EGFR and Ki-67 positive ex- pression of different age groups (P〉0.05); The positive rate of MGMT,EGFR and Ki-67 expression between male and female was not significantly different (P〈0.05). Further stratified analysis found that the expression of Ki-67 correlated well with each other (Ki-67 vs MGMT r=0. 296,P=0. 018; Ki-67 vs EGFR r=0. 466,P=0. 000). CONCLUSIONS:The expression level of MGMT, EGFR and Ki-67 are bound up with the different Pathological grading, and multy-parameterdetection can become the standard in estimating histological grade and improve the veracity of forecasting the prognosis.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第11期840-844,共5页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金(81071831) 江苏省卫生厅课题(H201021) 徐州医学院研究生科技创新工程项目(XTLC-1221)
  • 相关文献

参考文献8

  • 1孙增峰,李文良,谷峰,马勇杰.胶质瘤耐药相关机制的研究进展[J].中华肿瘤防治杂志,2011,18(7):551-556. 被引量:13
  • 2Wen PY, Kesari S. Malignant gliomas in adults[J]. N Engl J Med,2008,359(5) :492-507.
  • 3Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase I]1 study: 5-year analy sis of the EORTC-NCIC trial [ J ]. Lancet Oncol, 2009,10 ( 5 ) : 459- 466.
  • 4孙增峰,谷峰,李文良,马勇杰.替莫唑胺耐药机制的相关因素分析[J].中华肿瘤杂志,2011,33(10):794-796. 被引量:3
  • 5Riemenschneider MJ, Hegi ME, Reifenberger G. MGMTpromot- er methylation in malignant gliomas[J]. Targ Oncol, 2010,5 (3) :161-165.
  • 6Wang S, Zhao Y, Ruan Z, et al. Association between EGF - 61 G/A and glioma risk in a Chinese population [J]. BMC cancer, 2010,10(1):221.
  • 7Kondakova IV,Klisho EV,savenkova OV,et al. Matrix met all oproteinase 2 and 9 as the f act or of head and neck tumor metas- tasis[J] Biomed Khim,2008,54(5) :555-560.
  • 8钟喆,何正文,邱元,任年军,高洪波,章凯.人脑胶质瘤组织MMP-2和Ki-67表达及其相关性的初步研究[J].中华肿瘤防治杂志,2010,17(14):1070-1072. 被引量:6

二级参考文献28

  • 1Cavaliere R, Wen PY, Schiff D. Novel therapies for malignant gliomas. Neurol Clin, 2007, 25 : 1141-1171.
  • 2Ma J, Murphy M, O' Dwyer PJ, et al. Biochemical changes associated with a muhidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol, 2002, 63 : 1219-1228.
  • 3Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol, 2002, 20:2388-2399.
  • 4Middleton MR, Thatcher N, McMurry TB, et al. Effect of O^6-(4- bromothenyl) guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer, 2002, 100:615- 617.
  • 5Broniscer A, Gururangan S, MacDonald TJ, et al. Phase I trial of single-dose temozolomide and continuous administration of O^6- benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res, 2007, 13:6712-6718.
  • 6Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O^6-benzylguartine for patients with recurrent or progressive malignant glioma. J Clin Oncol, 2005, 23:7178-7187.
  • 7Rosati SF, Williams RF, Nunnally LC, et al. IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O^6-methylguanine DNA methyltransferase expression. Mol Cancer Ther, 2008, 7:3852-3858.
  • 8Ranson M, Middleton MR, Bridgewater J, et al. Lomeguatrib, a potent inhibitor of O^6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res, 2006, 12 : 1577-1584.
  • 9Turriziani M, Caporaso P, Bonmassar L, et al. O^6-(4-bromothenyl) guanine (PaTrin-2), a novel inhibitor of O^6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacol Res, 2006.53:317-323.
  • 10Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 2002, 21:5427-5440.

共引文献19

同被引文献168

  • 1张俊英,陈忠平.MGMT基因表达与人脑胶质瘤化疗耐药关系研究[J].中国神经肿瘤杂志,2003,1(4):200-204. 被引量:12
  • 2陈军,夏黎明,邹明丽,王荣华,冯定义,朱文珍,王承缘,周义成.星形细胞瘤MR波谱与细胞增殖活性的相关性研究[J].中华放射学杂志,2007,41(4):348-351. 被引量:2
  • 3许洪升,张俊英,岳伟英,牟永告,张湘衡,赛克,陈忠平.脑胶质瘤MGMT表达与体外药敏相关性及其临床意义[J].中国临床神经外科杂志,2007,12(5):263-266. 被引量:8
  • 4黄磊,江涛,袁芳,刘恩重.MGMT基因甲基化在胶质瘤化疗及预后中的意义[J].中国微侵袭神经外科杂志,2007,12(10):474-477. 被引量:9
  • 5Stupp R,Mason WP,van den Bent M J,et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J].N Engl J Med,2005,352:987-996.
  • 6Cameron W,Brennan B,Roel GW,et al.The somatic genomic landscape of glioblastoma[J].Cell,2013,155:462-477.
  • 7Ekstrand AJ,James CD,Cavenee WK,et al.Genes for epidermal growth factor receptor,transforming growth factor alpha,and epidermal growth factor and their expression in human gliomas in vivo[J].Cancer Res,1991,51:2164-2172.
  • 8Yin S,Van Meir EG.p53 pathway alterations in brain tumors.In:Van Meir EG,ed.CNS Cancer:Models,Markers,Prognostic Factors,Targets and Therapeutic Approaches[M].New York:Humana Press (Springer),2009:283-314.
  • 9Pedersen MW,Meltom M,Damstrup L,et al.The type Ⅲ epidermal growth factor receptor mutation-Biological significance and potential target for anti-cancer therapy[J].Ann Oncol,2001,12:745-760.
  • 10Tanaka K,Babic I,Nathanson D,et al.Oncogenic EGFR signaling activates an mTORC2-NF-kB pathway that promotes chemotherapy resistance[J].Cancer Discov,2011,1:524-538.

引证文献16

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部